Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase (BPNT2)
- Target
- BPNT2
- Molecular classification
- Enzyme, Nucleotidase, Inositol monophosphatase family
01
Overview
BPNT2 is a Golgi apparatus-localized enzyme of the inositol monophosphatase family that hydrolyzes phosphoadenosine phosphate (PAP) to adenosine monophosphate (AMP), especially regulating the removal of PAP produced during glycosaminoglycan sulfation by Golgi sulfotransferases. This function is fundamental in cartilage/bone formation through endochondral ossification. BPNT2 is implicated in genetic skeletal disorders (e.g., chondrodysplasia with joint dislocations) and immune dysregulation syndromes. There are no currently documented drugs that directly target BPNT2, but its enzymatic activity and gene mutations serve as critical biomedical research touchpoints.
- Other names
- 3'(2'), 5'-Bisphosphate nucleotidase 2IMPA3GPAPPIMPAD1Inositol monophosphatase domain-containing protein 1Inositol monophosphatase domain containing 1Phosphoadenosine phosphate 3'-nucleotidaseGolgi-resident nucleotide phosphataseMyo-inositol monophosphatase A3
02
Mechanism of action
Drugs would potentially act as enzyme inhibitors or modulators of PAP clearance or glycosaminoglycan sulfation, but no specific drug interactions are currently documented
03
Biological functions
Hydrolysis of phosphoadenosine phosphate (PAP) to adenosine monophosphate (AMP)Clearing PAP produced by Golgi sulfotransferases during glycosaminoglycan sulfationPossibly involved in skeletal development (endochondral ossification)
04
Disease associations
Chondrodysplasia with joint dislocations (Gpapp type)Spondyloenchondrodysplasia with immune dysregulation
05
Safety considerations
Disruption of BPNT2 activity is linked to skeletal disorders and immune dysregulationtherapeutic challenges may involve potential off-target effects impacting cartilage/bone development or immune function
06
Biomarkers
Mutations in BPNT2 gene have been associated with genetic disorders such as chondrodysplasia with joint dislocations
Beyond the preview
Go deeper on Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase (BPNT2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase (BPNT2).